3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
22
Prostatic Neoplasms
11
Breast Neoplasms
11
Triple Negative Breast Neoplasms
7
Fallopian Tube Neoplasms
7
Stomach Neoplasms
5
Neoplasm Metastasis
5
Sarcoma
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Metastatic Castration-resistant Prostate Cancer
4
Fanconi Anemia, Complementation Group D1
4
Small Cell Lung Carcinoma
3
Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Wilms Tumor
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Endometrial Neoplasms
2
Interventions
temsirolimus
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pazopanib
1
olaparib
1
eltrombopag
1
cc-486
1
Surveys and Questionnaires
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Doxorubicin
1
Docetaxel
1
Diphenhydramine
1
Cytarabine
1
Cyclophosphamide
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pathologic Complete Response
×
olaparib
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA